Health Technology Assessment, Value-Based Decision Making, and Innovation

Abstract

On behalf of the HTAi Policy ForumBackground: Identifying treatments that offer value and value for money is becoming increasingly important, with interest in how health technology assessment (HTA) and decision makers can take appropriate account of what is of value to patients and to society, and in the relationship between innovation and assessments of value. Methods: This study summarizes points from an Health Technology Assessment International (HTAi) Policy Forum discussion, drawing on presentations, discussions among attendees, and background papers. Results and Conclusions: Various perspectives on value were considered; most place patient health at the core of value. Wider elements of value comprise other benefits for: patients; caregivers; the health and social care systems; and society. Most decision-making systems seek to take account of similar elements of value, although they are assessed and combined in different ways. Judgment in decisions remains important and cannot be replaced by mathematical approaches. There was discussion of the value of innovation and of the effects of value assessments on innovation. Discussion also included moving toward "progressive health system decision making," an ongoing process whereby evidence-based decisions on use would be made at various stages in the technology lifecycle. Five actions are identified: (i) development of a general framework for the definition and assessment of value; development by HTA/coverage bodies and regulators of (ii) disease-specific guidance and (iii) further joint scientific advice for industry on demonstrating value; (iv) development of a framework for progressive licensing, usage, and reimbursement; and (v) promoting work to better adapt HTA, coverage, and procurement approaches to medical devices.

Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status

“…Another emerging trend in developed but also developing countries is the use of health technology assessment, or pharmacoeconomics or economic evaluation in decisions regarding the reimbursement for new products [30, 54, 62, 80, 82, 98–107]. This approach has many advantages, as it links reimbursement to the value of new products, but there are many challenges and issues to be considered.…”

Htai Policy Forum: Keeping Hta on Track

“…The publications developed from Policy Forum discussions (1)(2)(3)(4)(5)(6)(7)(8) are well worth reading and freely accessible on the HTAi website. Looking back at this output since 2007 gives an indication that "technology management" has been, in some shape or form, an area of interest for most meetings.…”

Treatment Is Worth a Lot - But Just How Much

“…Strains were becoming apparent even before the crunch of 2007-2008, but the crisis that precipitated is still reverberating across the member states, with growth sluggish or even negative, and prospects still sombre for recovery [4]. …”